Marks Group Wealth Management Inc raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 19.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,684 shares of the company’s stock after buying an additional 2,270 shares during the period. Marks Group Wealth Management Inc’s holdings in Johnson & Johnson were worth $2,425,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. ProShare Advisors LLC boosted its holdings in shares of Johnson & Johnson by 1.4% during the 1st quarter. ProShare Advisors LLC now owns 1,747,245 shares of the company’s stock worth $309,665,000 after buying an additional 24,086 shares during the period. Trek Financial LLC lifted its position in Johnson & Johnson by 6.2% during the first quarter. Trek Financial LLC now owns 5,582 shares of the company’s stock worth $989,000 after acquiring an additional 328 shares during the last quarter. Fishman Jay A Ltd. MI boosted its holdings in shares of Johnson & Johnson by 2.4% during the first quarter. Fishman Jay A Ltd. MI now owns 138,699 shares of the company’s stock worth $24,582,000 after acquiring an additional 3,250 shares during the period. Terril Brothers Inc. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $233,000. Finally, TD Asset Management Inc. increased its stake in shares of Johnson & Johnson by 6.9% during the first quarter. TD Asset Management Inc. now owns 3,264,881 shares of the company’s stock worth $578,635,000 after purchasing an additional 212,070 shares during the period. 68.78% of the stock is currently owned by institutional investors.
Johnson & Johnson Trading Down 0.3 %
JNJ opened at $165.58 on Thursday. The company’s 50 day moving average price is $173.23 and its two-hundred day moving average price is $174.42. The firm has a market capitalization of $435.34 billion, a price-to-earnings ratio of 24.10, a PEG ratio of 3.19 and a beta of 0.59. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. During the same period last year, the company earned $2.48 EPS. Johnson & Johnson’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is presently 65.79%.
Insiders Place Their Bets
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.35% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the company. Daiwa Capital Markets began coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. SVB Leerink dropped their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Wells Fargo & Company increased their price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Citigroup cut their target price on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.